Effects of xenogeneic adipose-derived stem cell transplantation on acute-on-chronic liver failure

Nanjing, China

Effects of xenogeneic adipose-derived stem cell transplantation on acute-on-chronic liver failure

Wei Zhu, Xiao-Lei Shi, Jiang-Qiang Xiao, Guang-Xiang Gu, Yi-Tao Ding and Zheng-Liang Ma

Nanjing, China

BACKGROUND:Adipose-derived stem cells (ADSCs) are particularly attractive in future clinical applications of stem cell-based therapy for acute-on-chronic liver failure (ACLF). This study was undertaken to evaluate the therapeutic potential of ADSCs on ACLF.

METHODS:ADSCs isolated from porcine fat tissue were expanded and labeled with BrdU. Rabbit models of ACLF were created by administration of D-Gal following CCl4-induced cirrhosis. One day after administration of D-Gal, rabbits of the ACLF/ADSCs group (n=15) were received ADSCs transplantation, while those in the ACLF/saline group (n=15) were treated with the same volume of saline. Biochemical parameters and histomorphological scoring were evaluated; the distribution and characteristics of transplanted ADSCs as well as the pathology of the liver were examined.

RESULTS:ADSCs transplantation improved the survival rate and the liver function of rabbits with ACLF. Biochemical parameters of the ACLF/ADSCs group were improved compared with those of the ACLF/saline group, and histomorphological scoring of the ACLF/ADSCs group was signif i cantly lower than that of the ACLF/saline group. ADSCs were identif i ed in the periportal region of the liver after cell transplantation.

CONCLUSION:Xenogenic ADSCs have therapeutic eff i cacy in the ACLF rabbit model.

(Hepatobiliary Pancreat Dis Int 2013;12:60-67)

adipose-derived stem cells; acute-on-chronic liver failure; cell transplantation

Introduction

Acute-on-chronic liver failure (ACLF) is the most common type of liver failure in China. In a large-scale study from 2002 to 2007 in China, 1813 (91.7%) of 1977 patients with liver failure were diagnosed with ACLF.[1,2]Patients with this disease have a poor outcome because most of them will develop into multi-organ failure following liver failure. Liver transplantation (LT) is the only curative option but limited by organ donor shortage, fi nancial consideration, and treatment of life-long immunosuppression.[3]

Recent studies[4-9]have shown that a number of different sources of stem cells can differentiate into hepatocytesin vitro, suggesting that stem cells may offer an alternative therapy for liver failure. Mesenchymal stem cells (MSCs) have been isolated from many adult and fetal tissues, including bone marrow,[4]adipose tissue,[5]amniotic fl uid (AF),[6]scalp tissue,[7]placenta,[8]and umbilical cord blood.[9]Particularly, bone marrow derived mesenchymal stromal cells (BMSCs) have been studied extensively because of their superior multipotency.[10-14]However, the amount of available bone marrow is usually not eff i cient, and the procurement procedure is invasive. On the other hand, adipose-derived stem cells (ADSCs) with biological properties similar to BMSCs[15]can also be induced to differentiate into various mesenchymal cell types[16-18]including hepatocytes.[19,20]Unlike BMSCs, ADSCs are present abundantly in the body, and they can be harvested repeatedly according to the procedure whichis simple and minimally invasive. These cells can be easily expanded and manipulatedin vitro. Therefore, ADSCs represent a potential source for cell therapy on liver diseases.

The purpose of this study was to evaluate the therapeutic potential of xenogeneic ADSC to treat ACLF. We successfully created a rabbit model of ACLF, and gained suff i cient quantities of ADSCs from swine. Porcine ADSCs then were transplanted into ACLF rabbits to investigate the effects of porcine ADSCs transplantation on ACLF.

Methods

Animals and reagents

New Zealand rabbits and outbred white pigs were obtained from the Animal Experimental Center of Nanjing Drum-Tower Hospital. All animal procedures were approved by the Animal Care Ethics Committees of Nanjing University Medical School and Nanjing Drum-Tower Hospital, and performed in accordance withGuide for the Care and Use of Laboratory Animals(NIH Publication 85-23 revised 1996, USA).[21]All chemicals were of analytical grade and purchased from GIBCO (USA) unless otherwise stated.

Isolation and culture of porcine ADSCs

Porcine fat tissue was obtained from male pigs and washed extensively with phosphate buffered saline (PBS). It was cut and minced into small pieces, and digested with 0.1% type I collagenase (Sigma, USA) under gentle shaking for 60 minutes at 37 ℃. Then DMEM/ F12 containing 10% fetal bovine serum was added to neutralize the enzyme activity. Cell suspension was fi ltrated sequentially through a 100-μm or 40-μm nylon mesh, washed via three centrifugations (50 g), and then resuspended in complete culture medium. Cells were incubated at 37 ℃ in a humidif i ed chamber containing 5% CO2for 24 hours. The adherent cells were further expanded with medium change at 3-day intervals.

BrdU labeling of ADSCs

ADSCs were labeled with BrdU (Sigma, USA) according to the manufacturer's instruction. Proliferation of cells was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide colorimetric assay daily from day 1 to day 10 after the labeling and growth curves were plotted. The percentage of the BrdU-labeled ADSCs was also examined with immunof l uorescence staining (described below). The viability of ADSCs was determined by trypan blue exclusion assay after they were detached with 0.25% trypsin and resuspended in PBS at 2×107cells/mL.

Flow cytometric analysis

The phenotype of porcine ADSCs was evaluated by fl ow cytometry analysis (FACS, Becton Dickinson, USA). Antibodies against the following cell surface markers were: phycoerythrin (PE)-conjugated CD45 (Antigenix America, USA), CD90, CD105, CD44, CD34 (Becton Dickinson, USA). Isotypic antibodies served as controls.

Induction of ACLF in rabbits

ACLF models were created in rabbits by CCl4intraperitoneal injection for 10 weeks, followed by venous injection with D-Galactosamine (D-Gal), as described by Brand?o.[22]

Experimental groups and transplantation of BrdU-labeled ADSCs into rabbits

After injection with D-Gal, ACLF rabbits were further divided into two groups: ACLF/ADSCs group (n=15) infused with 1×108porcine ADSCs on the second day, and ACLF/saline group (n=15) infused with the same volume of saline and served as controls.

Cell transplantation and surgical procedures were performed when rabbits were anesthetized with ether inhalation. An upper midline incision was made inferiorly from the xiphoid, and the portal vein was gently exposed with a moistened gauze. Freshly harvested porcine ADSCs (1×108) was suspended in 10 mL PBS and injected into the portal vein with a 25-gauge needle connected to a 2 mL syringe.

Assessment of liver function

At 1, 3, 5, 7, 14, 21 and 28 days after D-gal administration, blood was drawn from each rabbit into a heparin-containing tube and serum was collected after centrifugation for 10 minutes at 5000 rpm. Serum samples from all animals were taken to determine the levels of albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum ammonia (NH3), and total bilirubin (TBil) as well as prothrombin time (PT) by an automatic biochemical analyzer (Hitachi 7600, Tokyo, Japan).

Enzyme-linked immunosorbent assay for porcine albumin

The serum level of porcine albumin was quantif i ed by enzyme-linked immunosorbent assay (ELISA) using purif i ed goat anti-albumin and horseradish peroxidaseconjugated antibody (Bethyl Laboratories, USA). Theabsorbance was measured at 490 nm with a Cytof l uor multiwell plate reader (Benchmark, USA).

Survival rate and histology of the liver

ACLF rabbits were followed up for survival 28 days after D-Gal administration. Liver tissues were removed from each group for pathological examination. The time points were day 2, 7, 14, 21, and 28, respectively. After formalin fi xation and paraff i n embedding, the liver samples were sectioned into 4 μm slides and stained with hematoxylin-eosin (HE). Histological assessment was performed by a blinded observer using a previously described scoring method.[23]

Immunof l uorescence staining

Cultured cells or frozen tissue sections (6 μm in thickness) were incubated with either a mouse anti-BrdU antibody (dilution 1:1000; sigma, USA) alone or together with a goat anti-pig albumin antibody (dilution 1:500, bethyl, USA) at 4 ℃ overnight. These samples were further treated with a second antibody, FITC conjugated donkey anti-mouse IgG (H+L) (dilution 1:100; Jackson immunoResearch, USA) alone or together with a R-PE-conjugated donkey anti-goat IgG (H+L) (dilution 1:100; Jackson immunoResearch, USA). The nucleus was stained with Hoechst 33342 (1 mg/mL, beyotime, China).

Differentiation of transplanted ADSCs

The destination of transplanted ADSCs was assessed by immunof l uorescence double staining with antibodies against pig albumin and BrdU. Fluorescentin situhybridization (FISH) was also performed to identify the origin of cells in the liver following the Cambio protocol (Cambio, Cambridge, UK) (http://www.cambio. co.uk/).[24]

Statistical analysis

Statistical analysis was performed using the SPSS version 17.0. Data were expressed as mean±SD for values obtained from three repeated experiments/ measurements. Survival curves were calculated by the Kaplan-Meier method and analyzed with the Chi-square test. Statistical signif i cance was def i ned asP<0.05 using two-tailed unpaired Student'sttest or one-way analysis of variance or repeated measures analysis of variance.

Results

ADSCs in culture and labeling with BrdUThe freshly isolated ADSCs were small and approximately round cells, which then gradually grew into spindle or stellate-shaped cells (Fig. 1A). They proliferated rapidly and reached 90% conf l uency 3-4 days after they were passaged. After the second passage, ADSCs adopted a more uniform fi broblast-like morphology with long cell processes, and cell culture monolayer displayed the typical fi ngerprint-like pattern (Fig. 1B, C) similar to bone marrow stem cells.

After BrdU labeling and immunof l uorescence, labeled cells showed uniform fl uorescence signals (green) in the entire nucleus (Fig. 1D). After counter-stained with Hoechest-33342, the number of BrdU-positive cells was equal to that of Hoechest-positive cells at passage 0, and decreased over passages due to the proliferation of the labeled cells. However, at least half of the cells were still BrdU-positive after passages 5.

To examine whether BrdU labeling would adversely affect cell proliferation, we used the MTT assay to measure proliferation of the BrdU labeled or unlabeled cells. The proliferation rates from days 1-9 were not signif i cantly different in the two cell groups as shown by their growth curves (Fig. 2).

Expression of stem cell markers in ADSCs

Flow cytometric analysis revealed that few ADSCs expressed CD45 and CD34, and that over 90% of cells expressed CD44, CD90 and CD107 (Fig. 3). Such an expression prof i le is consistent with previous reports for porcine ADSCs.[25,26]

Fig. 1.Culture phenotypes of ADSCs. Morphology of porcine ADSCs in culture at passage 0 (A, original magnification ×40), and passage 5 (B, original magnification ×40; andC, original magnification ×100); BrdU labeling and immunofluorescence detection of ADSCs (D, original magnif i cation ×400).

Fig. 2.Growth curve of ADSCs with or without BrdU labels.

Fig. 3.Immunophenotype analysis of ADSCs from the porcine at the fifth passage by FACS. The MSCs were stained with monoclonal antibodies conjugated to PE against CD90, CD44, CD45, CD105 and CD34. The FACS results showed few ADSCs expressed CD45 and CD34, and that over 90% of cells expressed CD44, CD90 and CD107.

ADSC transplantation improves the survival rate of rabbits with ACLF

ADSCs were infused into ACLF rabbits 24 hours after D-Gal treatment. All the animals were followed up for 28 days, and the percentage of animals survived was graphed. As shown in Fig. 4, no rabbits died in the fi rst 24 hours after D-Gal injection; at 3 days, 73% and 47% of the animals survived in the ACLF/ADSCs and ACLF/ saline groups, respectively; at 7 days, the survival rate was 60% (9/15) and 27% (4/15) in the ACLF/ADSCs and ADSCs/saline groups, respectively (P<0.05).

Fig. 4.Survival curves of ACLF rabbits with or without ADSC transplantation. The survival rates of the ACLF/ADSCs group and ACLF/saline group were 60% and 27% respectively at the end of the 28 day period.

ADSC transplantation improves liver function of rabbits with ACLF

To examine the effect of ADSC transplantation on liver function of the ACLF rabbits, we measured the levels of ALT, AST, NH3, PT, TBil and albumin in the animals with or without ADSC transplantation. As shown in Fig. 5, all the surviving animals with ACLF displayed liver function abnormality. Elevated liver function induced by D-Gal administration peaked at 3 days and then gradually recovered to almost normal levels at 7 days. However, peak levels were signif i cantly lower in the ACLF/ADSC group than those in the ACLF/saline group (P<0.05). At the same time, D-Gal also signif i cantly reduced albumin levels, and the lowest albumin level in the ACLF/ADSCs group was signif i cantly higher than that in the ACLF/saline group (P<0.05). No signif i cant differences in these parameters were observed between the two groups after 7 days. However, the serum level of porcine albumin in all groups was undetected.

ADSC transplantation protects ACLF rabbits from liver damages

Fig. 5.Effect of ADSC transplantation on liver function. Serum biochemical parameters from ACLF rabbits showed the liver damage peaking at 3 days after D-Gal administration. Serum ALT, AST, TBil, NH3 and PT peak levels in the ACLF/ADSCs group were signif i cantly lower than those in the ACLF/saline group, and the lowest serum albumin level in the ACLF/ADSCs group was signif i cantly higher than that in the ACLF/saline group. There was no signif i cant difference in major serum biochemical parameters between these two groups after 7 days. *:P<0.05, compared with the ACLF/saline group.

The pathology of ACLF can be characterized by sequential changes in the liver tissue morphology with microscopic evaluation, consisting of ballooning and/or eosinophilic degeneration of hepatocytes, parenchymal necrosis or collapse with features of underlying chronic liver disease, especially fi brosis, which is different from that of normal tissues (Fig. 6A). After 10 weeks of CCl4treatment, all of the rabbits showed liver cirrhosis in HE-stained and Masson-stained sections (Fig. 6B, C). Two days after transplantation, liver samples from the ACLF/saline group displayed profound hepatocyte death, thickened septal fi brosis and severe distortion of tissue architecture (Fig. 6D), while those from the ACLF/ ADSC group showed only minor hepatocyte death with edema, thinner septal fi brosis and certain characteristics of tissue repair such as dual-core hepatocytes (Fig. 6E, F). Liver tissues taken from the ACLF/ADSC group at 28 days after D-Gal injection revealed almost normal hepatic trabecular architecture with moderate mononuclear inf i ltration, indicating a recovery from acute liver failure. At 3 months post-transplantation, we did not see any tumor development or abnormality in the liver, lung, bone marrow and other organs of the rabbits injected with ADSCs.

Semi-quantitative histological examination on liver tissues also revealed signif i cant differences in morphology between ACLF rabbits with or without ADSC transplantation. The average pathology scores of liver tissues obtained two days after transplantation were 1.8±0.6 and 2.9±0.8 in the ACLF/ADSC and ACLF/saline groups, respectively (P<0.05). These results demonstrated that ADSC therapy prevented histopathological changes in the liver of ACLF rabbits.

Fig. 6.Histology of the rabbit livers by HE or Masson staining. Liver tissue sections from rabbits in the ACLF/saline group showing normal morphology (A, HE, original magnif i cation ×100); rabbits treated with CCl4for 10 weeks showing a pseudolobe (B, HE;C, Masson, original magnif i cation ×100); rabbits in the ACLF/saline group at day 2 post-transplantation showing profound hepatocyte death, thickened septal fibrosis and severe distortion of tissue architecture (D, HE, original magnification ×100); liver tissue sections from the ACLF/ADSC group showing minor hepatocyte death with edema, thinner septal fibrosis (E, HE, original magnification ×100), and characteristic of tissue repair, such as dual-core hepatocytes was found in higher magnif i cation (F, HE, original magnif i cation ×400).

Differentiation of ADSCs towards hepatocytesin vivo

Using albumin as a molecular marker for hepatocytes, immunof l uorescence staining with antibody specif i c to porcine albumin revealed the presence of albumin positive cells derived from pig throughout the hepatic lobules at 14 and 21 days post-injection. These pig ADSC-derived hepatocytes distributed evenly among the periportal region and other parts of the liver. The number of albumin positive cells was lower at 14 days (Fig. 7A) than that at 21 days post-injection (Fig. 7B), indicating the enrichment of the differentiated cells over time. To follow the repopulation and differentiation of ADSC, FISH was performed to detect Y chromosomes in the female recipients. We found that male ADSC infused via the portal vein into female rabbit liver could engraftand differentiate into hepatocytes. Fourteen days after ADSC transplantation, some hepatocytes showed green signals in the nuclei stained with 4', 6-diamidino-2-phenylindole (DAPI) (Fig. 7C). Moreover, more donorderived hepatocytes were found in the injured liver of rabbits 21 days after treatment (Fig. 7D).

Fig. 7.Immunofluorescence detection of porcine ADSCs in the liver of ACLF rabbits. Double staining with antibody against BrdU (green) and anti-porcine albumin (red) with the nuclei stained with hoechst-33342 (blue) at 14 (A) and 21 days (B) after transplantation;C: Female liver after male ADSC transplantation for 14 days, some hepatocytes showed green signals in the nuclei stained with DAPI;D: Female liver after male ADSC transplantation for 21 days, the number of hepatocytes showing green signals increased.

Discussion

In this study, ADSCs isolated from porcine adipose tissues were similar to other MSCs in morphology when cultured. Interestingly, they had a higher proliferation than MSCs which was also derived from adipose tissue reported by Zuk et al.[27]After culture expansion, their yield was 40-fold higher than that of several other types of BMSCs.[15]Various studies[28,29]have demonstrated the immunosuppressive characteristic of MSCsin vitroandin vivo.A recent study also indicated that this immunosuppression may partially due to chemokines and immune-inhibitory nitric oxide or indoleamine 2, 3-dioxygenase produced by MSCs.[30]ADSCs showed immunosuppressive properties of inhibiting mixed lymphocyte proliferation as well, which may share the same immunosuppressive mechanism with MSCs, and the cell-cell contact was required for ADSC-mediated full immunosuppression. These results suggest that ADSCs possess the low immunogenicity and can escape from immune response.[28,31]Thus, the cells may be robustly expanded for a variety of therapeutic applications and offer a rich source for stem cell-based therapy.[32,33]

We studied the implantation and differentiation of ADSCsin vivoafter they were labeled by BrdU, an S-phase marker that can be incorporated into newly synthesized DNA during the DNA replication. The BrdU-positive cells were detectable from half a day to 28 days post-transplantation, shown with their clear morphology by immunostainning against BrdU, suggesting that BrdU is relatively safe and stable for labeling stem cells. Banas et al[20]observed reduction of serum ammonia level and ALT after ADSCs transplantation. In the current study, similar results were found that ADSC transplantation signif i cantly improved the liver function of ACLF rabbits, and prolonged their survival time. This improvement was paralleled to the change of engrafted ADSCs quantity, suggesting that the improvement of liver function may be mediated by ADSCs engraftment. Since liver histopathology is often used for the diagnosis and assessment of ACLF, and it is also associated with the outcome in ACLF patients,[34]we assessed liver pathology by a semi-quantitative scoring system. The average pathology score in ACLF rabbits transplanted with ADSCs was much lower than that in the ACLF/saline group. Consistent with this, microscopic examination revealed that ADSCs inhibited death and promoted regeneration of hepatocytes.

In our pilot experiments, ALF was induced by a single injection of D-Gal without pretreatment with CCl4in rabbits. In these animals, transplantation of ADSCs did not restore liver function, suggesting that cell transplantation may be not eff i cient in ALF conditions except ACLF. In other pilot experiments with the ACLF models, engrafted ADSCs quantity related liver function improvement was verif i ed. In this current study, transplanted ADSCs were fi rst concentrated in the portal areas 3 days after D-Gal injection and then more widely distributions were performed at 7, 14, 21 days post-injection (not shown), indicating their migrationin vivo. We also found that some cells positive for BrdU also expressed albumin. However, we have not adequately proven hepatogenic differentiation of ADSCsin vivo. To clarify the mechanism, we will perform dual FISH for porcine DNA and albumin.

It is still not clear that by which mechanisms the transplanted cells improve the liver function. Hepatic regeneration may have multiple pathways to accomplish cell replacement and organ repair. The mechanisms of improved liver function may be due to cytokine production from transplanted ADSCs. It has beenreported that ADSCs can secret several potentially benef i cial growth factors, such as vascular endothelial growth factor, hepatocyte growth factor, basic fi broblast growth factor, transforming growth factor-β, and insulin-like growth factor-1.[35-37]ADSCs have also shown to produce signif i cantly more bioactive factors than BMSCs,[38]therefore, they may have an equal or even stronger regenerative effect on implanted tissues than BMSCs. Also, researches have shown that ADSCs could inhibit the inf l ammatory reaction to reduce injury.[39-42]Moreover, some studies[42,43]have shown that regenerating hepatocytes in transplant recipients may be derived from MSCs that fused with host hepatocytes. However, recent reports[44,45]have indicated that bone marrow cells and hematopoietic stem cells can convert into hepatocytes without fusion. Therefore, we considered a possibility that all situations mentioned above simultaneously happened in the ADSCs transplantation for ACLF model. It is necessary to verify this possibility in further study.

In conclusion, this study generated the fi rst rabbit ACLF, and successfully transplanted ADSCs into the livers of this model. ADSCs transplantation prolonged the survival of ACLF animals by improving their liver function. Although the underlying mechanisms are not clear, these cells present a valuable source of stem cells with great potentiality and promise for future clinical applications.

Contributors:DYT and MZL contributed equally to this work. ZW, DYT and MZL participated in research design. ZW, XJQ and GGX accomplished this research. SXL and XJQ drafted the paper. MZL is the guarantor.

Funding:This work was supported by a grant from the National Natural Science Foundation of China (30901431).

Ethical approval:All animal procedures were approved by the Animal Care Ethics Committee of Nanjing University Medical School and Nanjing Drum-Tower Hospital.

Competing interest:No benef i ts in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

1 Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacif i c Association for the Study of the Liver (APASL). Hepatol Int 2009;3:269-282.

2 Liu XY, Hu JH, Wang HF, Chen JM. Etiological analysis of 1977 patients with acute liver failure, subacute liver failure and acute-on-chronic liver failure. Zhonghua Gan Zang Bing Za Zhi 2008;16:772-775.

3 Sass DA, Shakil AO. Fulminant hepatic failure. Liver Transpl 2005;11:594-605.

4 Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.

5 Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-4295.

6 De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;25:100-106.

7 Shih DT, Lee DC, Chen SC, Tsai RY, Huang CT, Tsai CC, et al. Isolation and characterization of neurogenic mesenchymal stem cells in human scalp tissue. Stem Cells 2005;23:1012-1020.

8 In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004;22:1338-1345.

9 Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004;22:625-634.

10 Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, et al. Adult bone marrow stromal cells differentiate into neural cellsin vitro. Exp Neurol 2000; 164:247-256.

11 Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;279: 1528-1530.

12 Zhang S, Jia Z, Ge J, Gong L, Ma Y, Li T, et al. Purif i ed human bone marrow multipotent mesenchymal stem cells regenerate infarcted myocardium in experimental rats. Cell Transplant 2005;14:787-798.

13 Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, et al.In vitrohepatic differentiation of human mesenchymal stem cells. Hepatology 2004;40:1275-1284.

14 Snykers S, Vanhaecke T, Papeleu P, Luttun A, Jiang Y, Vander Heyden Y, et al. Sequential exposure to cytokines ref l ecting embryogenesis: the key forin vitrodifferentiation of adult bone marrow stem cells into functional hepatocyte-like cells. Toxicol Sci 2006;94:330-241.

15 Peng L, Jia Z, Yin X, Zhang X, Liu Y, Chen P, et al. Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev 2008; 17:761-773.

16 Miranville A, Heeschen C, Sengenès C, Curat CA, Busse R, Bouloumié A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004;110:349-355.

17 Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004;109:656-663.

18 Safford KM, Hicok KC, Safford SD, Halvorsen YD, Wilkison WO, Gimble JM, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun 2002;294:371-379.

19 Seo MJ, Suh SY, Bae YC, Jung JS. Differentiation of human adipose stromal cells into hepatic lineagein vitroandin vivo. Biochem Biophys Res Commun 2005;328:258-264.

20 Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Quinn G, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007;46: 219-228.

21 Bayne K. Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. Physiologist. 1996;39:199,208-211.

22 Brand?o CG, Ferreira HH, Piovesana H, Polimeno NC, Ferraz JG, de Nucci G, et al. Development of an experimental model of liver cirrhosis in rabbits. Clin Exp Pharmacol Physiol 2000;27:987-990.

23 Nakaji M, Hayashi Y, Ninomiya T, Yano Y, Yoon S, Seo Y, et al. Histological grading and staging in chronic hepatitis: its practical correlation. Pathol Int 2002;52:683-690.

24 Zheng JF, Liang LJ. Intra-portal transplantation of bone marrow stromal cells ameliorates liver fi brosis in mice. Hepatobiliary Pancreat Dis Int 2008;7:264-270.

25 Williams KJ, Picou AA, Kish SL, Giraldo AM, Godke RA, Bondioli KR. Isolation and characterization of porcine adipose tissue-derived adult stem cells. Cells Tissues Organs 2008;188:251-258.

26 Meliga E, Strem BM, Duckers HJ, Serruys PW. Adiposederived cells. Cell Transplant 2007;16:963-970.

27 Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-228.

28 Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng 2007; 13:1185-1195.

29 Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant 2007;16:555-562.

30 Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150.

31 Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose tissuederived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005;129:118-129.

32 Tchkonia T, Tchoukalova YD, Giorgadze N, Pirtskhalava T, Karagiannides I, Forse RA, et al. Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am J Physiol Endocrinol Metab 2005;288:E267-277.

33 Lacasa D, Agli B, Moynard D, Giudicelli Y. Evidence for a regional-specif i c control of rat preadipocyte proliferation and differentiation by the androgenic status. Endocrine 1995; 3:789-793.

34 Rastogi A, Kumar A, Sakhuja P, Bihari C, Gondal R, Hissar S, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011; 459:121-127.

35 Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004;109:1292-1298.

36 Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa T, Takami Y, et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005;25:2542-2547.

37 Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007;363:674-679.

38 Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, et al. IFATS collection:in vivotherapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 2008;26:2705-2712.

39 Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010;20:510-518.

40 Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-49.

41 Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008;26:151-162.

42 Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, et al. Cell fusion is the principal source of bonemarrow-derived hepatocytes. Nature 2003;422:897-901.

43 Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature 2003;422:901-904.

44 Harris RG, Herzog EL, Bruscia EM, Grove JE, Van Arnam JS, Krause DS. Lack of a fusion requirement for development of bone marrow-derived epithelia. Science 2004;305:90-93.

45 Jang YY, Collector MI, Baylin SB, Diehl AM, Sharkis SJ. Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol 2004;6:532-539.

Received July 31, 2012

Accepted after revision December 5, 2012

AuthorAff i liations:The Combination of Chinese Medicine with Western Medicine Gulou Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210008, China (Zhu W); Department of Anesthesiology (Zhu W and Ma ZL); Department of Hepatobiliary Surgery (Shi XL, Xiao JQ and Ding YT), Aff i liated Drum-Tower Hospital, Nanjing University Medical School, Nanjing 210008, China; Jiangsu Province's Key Medical Center for Hepatobiliary Disease, Nanjing 210008, China (Shi XL, Xiao JQ, Gu GX and Ding YT)

Zheng-Liang Ma, MD, Department of Anesthesiology, Aff i liated Drum-Tower Hospital, Nanjing University Medical School, Nanjing 210008, China (Tel: 86-25-83105502; Fax: 86-25-83317016; Email: mazhengliang1964@yahoo.com.cn)

? 2013, Hepatobiliary Pancreat Dis Int. All rights reserved.

10.1016/S1499-3872(13)60007-7